The controlled collection and processing of clinical specimens from patients with acute and chronic leukemias, myelodysplastic syndromes (MDS), and myeloproliferative disorders (MPD) is a critical activity for an efficient and comprehensive program in translational research in hematologic malignancies. Accordingly, the Biospecimen Core (Core A) has one overarching aim: We will collect, store, process, and distribute biospecimens from all patients with a diagnosis of leukemia, MDS, and MPD seen at this institution to facilitate biospecimen-based translational research: We will collect malignant cell populations from bone marrow aspirates and peripheral blood, as well as skin punch biopsy and buccal lavage specimens representing non-malignant cell populations. Serum and plasma will be collected for future proteomic biomarker studies. Specimens will be collected throughout each patient's disease course (initial presentation, remission, relapse) and where appropriate, archival specimens from previous malignancies will be retrieved. Particular attention to specimen procurement (eg. rapid processing of leukemia cells to preserve transcript profiles) and quality control will be practiced. Specimens will be processed to cellular RNA, genomic DNA, whole genome amplified DNA, and protein extracts as required for each study. Cellular populations will also be viably frozen for future xenograft studies. In collaboration with the Flow Cytometry Shared Resource of our Cancer Center, we will process and distribute specimens from flow-sorted cell populations. In collaboration with our clinical Laboratory of Cytogenetics and Cytogenomics, we will ensure that all specimens used for research are extensively and accurately annotated with molecular diagnostic data.
The aims of this Core will be accomplished by expanding the scope of a well-established Cancer Center Tumor Bank and an on-going, funded P01 effort to collect AML and MDS biospecimens for genomic analysis. Specifically, Gore A will expand the number and types of leukemia patients from whom biospecimens will be collected, and serve as a conduit (through data and specimen sharing) to allow for a broader variety of translational research studies in hematologic malignancies, using new and previously banked biospecimens.

Public Health Relevance

The proposed studies will lead to both an improved understanding of the pathogenesis and new approaches to the detection, prevention and treatment of hematologic malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA171963-01A1
Application #
8595804
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2013-09-03
Project End
2018-06-30
Budget Start
2013-09-03
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$209,445
Indirect Cost
$79,913
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Duncavage, Eric J; Jacoby, Meagan A; Chang, Gue Su et al. (2018) Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med 379:1028-1041
Khoury, Hanna Jean; Langston, Amelia A; Kota, Vamsi K et al. (2018) Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant 53:826-831
Schroeder, Mark A; Choi, Jaebok; Staser, Karl et al. (2018) The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant 24:1125-1134
Perry, Justin S A; Russler-Germain, Emilie V; Zhou, You W et al. (2018) CD36 Mediates Cell-Surface Antigens to Promote Thymic Development of the Regulatory T Cell Receptor Repertoire and Allo-tolerance. Immunity 48:923-936.e4
Wong, Terrence N; Miller, Christopher A; Jotte, Matthew R M et al. (2018) Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun 9:455
Christopher, Matthew J; Petti, Allegra A; Rettig, Michael P et al. (2018) Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med 379:2330-2341
Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521
Jacoby, Meagan A; Duncavage, Eric J; Chang, Gue Su et al. (2018) Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight 3:
Monlish, Darlene A; Bhatt, Sima T; Duncavage, Eric J et al. (2018) Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS. Blood 131:1032-1035
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494

Showing the most recent 10 out of 64 publications